Skip to main content
Fig. 2 | Molecular Cancer

Fig. 2

From: A combined computational and functional approach identifies IGF2BP2 as a driver of chemoresistance in a wide array of pre-clinical models of colorectal cancer

Fig. 2

RNA expression of members of the IGF2/AKT axis in human CRC samples and independency of IGF2BP2 expression regarding BRAF and KRAS mutational status. A-D RNA expression using RPKM values of IGF2, IGF1R, PTEN, and IGF2R from RNA-Seq data [31] of primary tumor tissue (primary tumor, n = 88), normal colon tissue (colon, n = 22), tissue from liver metastases (liver metastases, n = 23), and non-neoplastic hepatic tissue (liver, n = 12). E IGF2BP2 expression in primary and metastatic tumors grouped in BRAF and KRAS wild-type (wt) samples, samples carrying either KRAS or BRAF mutations (KRAS or BRAF), and samples with BRAF (BRAF) or KRAS (KRAS) mutations. Statistical significance was determined by Mann-Whitney U Test as data were not normally distributed

Back to article page

Molecular Cancer

ISSN: 1476-4598